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Background
Fresh red cells may improve outcomes in critically ill patients by enhancing oxy-
gen delivery while minimizing the risks of toxic effects from cellular changes and 
the accumulation of bioactive materials in blood components during prolonged 
storage.
Methods
In this multicenter, randomized, blinded trial, we assigned critically ill adults to 
receive either red cells that had been stored for less than 8 days or standard-issue 
red cells (the oldest compatible units available in the blood bank). The primary 
outcome measure was 90-day mortality.
Results
Between March 2009 and May 2014, at 64 centers in Canada and Europe, 1211 pa-
tients were assigned to receive fresh red cells (fresh-blood group) and 1219 patients 
were assigned to receive standard-issue red cells (standard-blood group). Red cells 
were stored a mean (±SD) of 6.1±4.9 days in the fresh-blood group as compared 
with 22.0±8.4 days in the standard-blood group (P<0.001). At 90 days, 448 patients 
(37.0%) in the fresh-blood group and 430 patients (35.3%) in the standard-blood 
group had died (absolute risk difference, 1.7 percentage points; 95% confidence 
interval [CI], –2.1 to 5.5). In the survival analysis, the hazard ratio for death in the 
fresh-blood group, as compared with the standard-blood group, was 1.1 (95% CI, 
0.9 to 1.2; P = 0.38). There were no significant between-group differences in any of 
the secondary outcomes (major illnesses; duration of respiratory, hemodynamic, or 
renal support; length of stay in the hospital; and transfusion reactions) or in the 
subgroup analyses.
Conclusions
Transfusion of fresh red cells, as compared with standard-issue red cells, did not 
decrease the 90-day mortality among critically ill adults. (Funded by the Cana-
dian Institutes of Health Research and others; Current Controlled Trials number, 
ISRCTN44878718.)
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Blood transfusions are adminis-tered frequently and may have unintended consequences in critically ill patients.1-4 
Current regulations permit the storage of red 
cells for up to 42 days, but prolonged storage has 
been associated with changes that may render 
red cells ineffective as oxygen carriers and that 
lead to the accumulation of substances that have 
untoward biologic effects.5-8
A systematic review of 18 observational stud-
ies involving a total of 409,840 patients and 
three randomized, controlled trials involving a 
total of 126 patients suggested that the transfu-
sion of older red cells, as compared with newer 
red cells, was associated with a 16% increase in 
the risk of death.9 However, a recent randomized 
trial did not document adverse consequences on 
oxygenation, immunologic, or coagulation vari-
ables in 50 patients undergoing mechanical 
ventilation who received red-cell units that had 
been stored for a median of 4.0 days, as compared 
with 50 patients who received blood that had 
been stored for 26.5 days.10 In the Age of Blood 
Evaluation (ABLE) pilot trial involving 66 pa-
tients, 27% of the patients who received fresh 
blood, as compared with 13% assigned to stan-
dard-issue blood, died or had a life-threatening 
complication (P = 0.31).11
Blood-transfusion services typically provide 
the oldest compatible red cells as an inventory-
management approach (“first in, first out”) to 
minimize waste of blood components. This prac-
tice is amplified at large centers, because suppliers 
send fresh red cells to small centers or remote 
locations where usage is low. Frequently, unused 
older red cells are returned from these centers 
for redistribution to larger centers, thus expos-
ing some of the sickest patients in any system to 
the oldest available blood. We hypothesized that 
among critically ill adults, fresh red cells stored 
for less than 8 days would be superior to stan-
dard-issue red cells, resulting in lower mortality 
at 90 days.
Me thods
Study Design and Oversight
The ABLE trial was a multicenter, randomized, 
blinded trial comparing red cells stored for less 
than 8 days with standard-issue red cells. Ran-
domization was performed with the use of a cen-
tralized computer-generated assignment sequence, 
with stratification according to study site. Critically 
ill patients were assigned in a 1:1 ratio to one of the 
two study groups, with the use of permuted blocks 
of varying sizes of 6, 8, or 10. Randomization was 
initiated by blood-transfusion personnel when the 
first red-cell transfusion was requested. Only the 
study statistician at the coordinating center had 
knowledge of the randomization codes. An opaque 
sticker was affixed over the expiration and collec-
tion dates on the blood units, or the labels were 
changed, so that the medical team would be un-
aware of the treatment-group assignments. Blood-
transfusion technologists refrained from releasing 
information on storage duration to all clinical and 
research personnel.
The conduct of the trial and the safety of par-
ticipants were overseen by the data and safety 
monitoring committee, whose members reviewed 
interim analyses after each consecutive group of 
500 patients had been followed for 90 days. We 
adopted O’Brien–Fleming group-sequential stop-
ping rules for the four interim analyses. All data 
management and statistical analyses were per-
formed by the Methods Centre at the Ottawa Hos-
pital Research Institute in Ottawa. Clinical coordi-
nation was conducted by the Research Center of 
Sainte-Justine Hospital in Montreal. The trial was 
conducted with the support of the Canadian Criti-
cal Care Trials Group.
The protocol, including details of trial conduct 
and the statistical analysis plan, has been pub-
lished previously12 and is available with the full 
text of this article at NEJM.org. The study protocol 
was approved by the local or regional research eth-
ics board for each participating institution. The 
study was designed by the authors, who vouch for 
the accuracy and completeness of the data and for 
the fidelity of this report to the study protocol. No 
one who is not an author contributed to the writing 
of the paper. There was no support from a com-
mercial entity for this study. At sites where deferred 
consent was permitted, written informed consent 
was obtained from the patient or surrogate deci-
sion maker as soon as possible after enrollment. If 
consent was declined, the study intervention was 
stopped, but we explicitly requested to keep all 
information on patients who had been enrolled in 
the trial and ascertain 90-day follow-up data.
Study Population
We enrolled critically ill adults from tertiary care 
intensive care units (ICUs) at 64 centers (26 in 
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Canada, 20 in the United Kingdom, 10 in France, 
7 in the Netherlands, and 1 in Belgium) (see the 
Supplementary Appendix, available at NEJM.org). 
We selected study sites at which all red-cell units 
were leukoreduced before storage and suspended 
in saline–adenine–glucose–mannitol (SAGM) ad-
ditive solutions.
We screened patients 18 years of age or older 
who were admitted to participating ICUs. Pa-
tients were eligible if a first red-cell transfusion 
was prescribed within 7 days after admission to 
the ICU and if they were expected to require 
invasive or noninvasive mechanical ventilation 
for at least 48 hours. Reasons for exclusion of 
patients are listed in Figure S1 in the Supple-
mentary Appendix.
Intervention
We compared the use of fresh red cells that had 
been stored for less than 8 days with the usual 
transfusion practice, whereby blood-transfusion 
services issue the oldest available compatible 
blood. Participating blood-transfusion services 
in collaboration with blood centers agreed to 
maintain an inventory of fresh red cells for pa-
tients assigned to the fresh-blood group. We an-
ticipated that compatible red cells stored for less 
than 8 days might not always be available to pa-
tients assigned to receive fresh red cells. In such 
instances, the protocol specified that patients as-
signed to the fresh-blood group receive the fresh-
est compatible red cells (i.e., not the oldest com-
patible, as issued in the standard-blood group). 
For this clinical trial, we defined adherence to 
the transfusion protocol for the fresh-blood 
group as the transfusion of red-cell units that 
had been stored for less than 8 days and for the 
standard-blood group as the transfusion of the 
oldest compatible red cells. We administered the 
study interventions until hospital discharge, 
death, or up to 90 days after randomization, 
whichever occurred first. There were no other 
trial interventions related to red cells or other 
blood products. We did not mandate or monitor 
any bedside transfusion guidelines. All decisions 
regarding patient care were at the discretion of 
the attending physicians and the clinical team.
Outcomes
The primary outcome measure was 90-day all-cause 
mortality. We ascertained survival status by direct 
contact with clinical teams, patients, or families 
and occasionally by contact with primary care phy-
sicians or by review of vital-statistics registries.
We also collected information on several sec-
ondary outcomes, including organ dysfunction.13 
We recorded infections, including nosocomial 
pneumonia, deep-tissue infections (peritonitis and 
mediastinitis), and bacteremia, which we catego-
rized according to Centers for Disease Control 
criteria.14 We examined the length of stay in the 
ICU and in the hospital as well as the duration 
of respiratory, hemodynamic, or renal support. 
Adverse events and transfusion reactions were 
recorded daily. Patient data were abstracted from 
hospital charts. Information on the duration of 
red-cell storage was provided by blood-bank tech-
nologists.
Statistical Analysis
We estimated that a total sample of 2266 patients 
would be needed for the study to have 90% power 
to detect an absolute difference in risk of 5 per-
centage points from a baseline mortality of at 
least 25%, at a type I error rate of 5% (two-sided 
alpha). With an anticipated rate of loss to follow-
up at 90 days of 5%, we calculated that 2510 pa-
tients would have to undergo randomization.15
All the statistical analyses were based on the 
intention-to-treat principle. We also performed 
two prespecified analyses of 90-day mortality: 
first, we performed a per-protocol analysis that 
was limited to patients who received at least one 
red-cell transfusion after randomization; second, 
as a sensitivity analysis, we restricted our analysis 
to patients in the fresh-blood group who received 
only units stored for less than 8 days versus pa-
tients in the standard-blood group who received 
only units stored for more than 7 days. We calcu-
lated the absolute risk difference (risk in the 
fresh-blood group minus risk in the standard-
blood group) with 95% confidence intervals for 
all mortality analyses, including 90-day mortal-
ity. A positive value suggested increased mortal-
ity or number of events in the fresh-blood group, 
whereas a negative value suggested a greater num-
ber of events in the standard-blood group. We 
compared continuous measures, including length 
of stay in the hospital or ICU and duration of 
respiratory, hemodynamic, or renal support, using 
the Wilcoxon rank-sum test.
We used multivariable logistic-regression mod-
els to calculate absolute risk differences while 
adjusting for possible independent confounding 
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variables, including center, patient age, sex, co-
existing illnesses, illness-severity score on the 
Acute Physiology and Chronic Health Evaluation 
II (APACHE II; range, 0 to 71, with higher scores 
indicating a greater risk of death),16 and the Mul-
tiple Organ Dysfunction Score (range, 0 to 24, 
with higher scores indicating more severe organ 
dysfunction).17 We also compared Kaplan–Meier 
survival curves, with time to death censored at 
90 days as the outcome. We compared treatment 
effects using a log-rank test, followed by Cox 
proportional-hazards modeling with the same 
explanatory variables used in the logistic-regres-
sion models. This approach was used for the 
secondary outcomes of all-cause mortality at 28 
days, as well as mortality in the hospital or ICU.
Prespecified subgroup analyses of 90-day all-
cause mortality were performed according to age 
(<40 years, 40 to <50 years, 50 to <60 years, or 
≥60 years), APACHE II score (<20 vs. ≥20), num-
ber of red-cell units transfused (1 to 3 vs. >3), and 
admission category (medical, surgical, or trau-
ma). The same multivariable logistic-regression 
models were used in each subgroup stratum.
Dichotomous data are presented as numbers 
and percentages, whereas continuous data are 
expressed as means and standard deviations or 
medians and interquartile ranges, as appropriate. 
We report 95% confidence intervals. P values have 
not been adjusted for multiple comparisons. Data 
were analyzed with the use of SAS software, ver-
sion 9.1 (SAS Institute).
Table 1. Baseline Characteristics.*
Characteristic
Fresh Blood
(N = 1206)
Standard Blood
(N = 1206)
Total
(N = 2412)
Age — yr 61.3±16.7 61±16.7 61.2±16.7
Male sex — no. (%) 682 (56.6) 643 (53.3) 1325 (54.9)
Coexisting illness — no. (%) 512 (42.5) 514 (42.6) 1026 (42.5)
APACHE II score† 21.9±7.7 21.6±7.6 21.8±7.6
Length of stay in ICU — days 2.4±2.0 2.4±2.1 2.4±2.1
Time from hospitalization to ICU admission — days 2.6±6.6 2.7±6.5 2.6±6.5
Organ injury and support
MODS‡ 5.0±3.1 4.7±3.1 4.9±3.1
Invasive mechanical ventilation — no. (%) 1176 (97.5) 1174 (97.3) 2350 (97.4)
Renal-replacement therapy — no. (%)§  324 (26.9)  354 (29.4)  678 (28.1)
Vasoactive support — no. (%)¶  750 (62.2)  765 (63.4) 1515 (62.8)
Type of admission — no. (%)
Emergency 1164 (96.5) 1169 (96.9) 2333 (96.7)
Elective  42 (3.5)  37 (3.1)  79 (3.3)
Major admission category — no. (%)‖
Medical  845 (70.1)  867 (71.9) 1712 (71.0)
Surgical  175 (14.5)  152 (12.6)  327 (13.6)
Trauma
Brain injury 110 (9.1) 106 (8.8) 216 (9.0)
No brain injury  76 (6.3)  80 (6.6) 156 (6.5)
* Plus–minus values are means ±SD. ICU denotes intensive care unit.
† Scores on the Acute Physiology and Chronic Health Evaluation II (APACHE II) range from 0 to 71, with higher scores 
indicating a higher risk of death.16
‡ The Multiple Organ Dysfunction Score (MODS) ranges from 0 to 24, with higher scores indicating more severe organ 
dysfunction.17
§ Renal-replacement therapy included continuous renal-replacement therapy, peritoneal dialysis, or hemodialysis.
¶ Vasoactive support was defined as continuous vasoactive drug infusion for hemodynamic support (excluding dopa-
mine infusion at a dose of ≤5 µg per kilogram of body weight per minute).
‖ Major admission category was missing for one patient in the standard-blood group.
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R esult s
Patients
From March 2009 through May 2014, a total of 
19,196 patients were eligible for inclusion. Of these, 
16,605 patients (86.5%) met at least one exclusion 
criterion; the patient or a surrogate decision maker 
declined consent in 81 instances. Therefore, 2510 
patients underwent randomization; 80 (3.2%) were 
withdrawn after randomization because we were 
unable to obtain primary outcome data, leaving 
2430 patients (1211 in the fresh-blood group and 
1219 in the standard-blood group) in the intention-
to-treat analysis (Fig. S1 in the Supplementary Ap-
pendix). Baseline data were available for 1412 of the 
1430 patients with primary outcome data. Of these 
2430 patients, 94 (3.9%) did not receive any red-cell 
transfusions. The two study groups had similar 
characteristics at baseline (Table 1). The overall rate 
of loss to follow-up was 3.2% at 90 days.
Intervention
A total of 5198 red-cell units were given to patients 
in the fresh-blood group and 5210 to patients in 
the standard-blood group (Table 2). The average 
duration of storage was 6.1±4.9 days in the fresh-
blood group versus 22.0±8.4 days in the stan-
dard-blood group (P<0.001). The rate of adher-
ence to the transfusion protocol was 95.4% for 
all red cells transfused, with 100% of patients in 
the standard-blood group receiving only stan-
dard-issue red cells and 84.0% of patients in the 
fresh-blood group receiving only red cells stored 
for less than 8 days (Table 2, and Fig. S2 in the 
Supplementary Appendix). In the fresh-blood 
group, all the patients received the freshest red 
cells available (i.e., there were no protocol viola-
tions). Only 6.6% of the patients in the fresh-
blood group received more than 1 red-cell unit 
that had been stored for more than 7 days, and 
only 4.6% received more than 2 units that had 
been stored for more than 7 days. Most patients 
in the fresh-blood group (238 of 249 patients 
[95.6%]) who received only 1 red-cell transfusion 
received exclusively red-cell units that had been 
stored for less than 8 days (Table S2 in the Sup-
plementary Appendix). Cointerventions were 
similar in the two groups before and after ran-
domization (Table 1, and Table S3 in the Supple-
mentary Appendix).
Table 2. Anemia and Red-Cell Transfusions.*
Variable Fresh Blood Standard Blood P Value
Hemoglobin level in ICU
No. of patients evaluated 1207 1206
Level before first transfusion — g/dl 7.69±1.28 7.64±1.09 0.27
Lowest level after randomization — g/dl 7.34±1.46 7.31±1.41 0.61
Red-cell transfusions after randomization
Patients who received at least one transfusion — no./total no. (%)† 1163/1207 (96.4) 1173/1208 (97.1) 0.30
Time from randomization to first transfusion — hr 10.3±16.2 9.7±16.2 0.43
No. of red-cell units per patient who received at least one transfusion 4.3±5.2 4.3±5.5 0.98
Duration of storage of all red-cell units — days 6.1±4.9 22.0±8.4 <0.001
Adherence to transfusion protocol — no./total no. (%)
Patients‡ 977/1163 (84.0) 1206/1206 (100) <0.001
Red-cell units§ 4723/5198 (90.9) 5210/5210 (100) <0.001
* Plus–minus values are means ±SD.
† Baseline data on 2 patients in the standard-blood group who received a transfusion were missing. Data on transfusion were missing for 36 
patients (15 patients in the fresh-blood group and 21 patients in the standard-blood group).
‡ Patients assigned to the fresh-blood group were considered to be adherent to the transfusion protocol if they received red-cell transfusions 
only with units stored for less than 8 days; patients assigned to the standard-blood group were considered to be adherent if they received 
transfusions of the oldest available compatible red cells.
§ For red-cell units, adherence was defined as (number of red-cell units transfused that were stored ≤7 days) ÷ (total number of red-cell units 
transfused) among patients assigned to the fresh-blood group and as (number of standard-issue red-cell units transfused) ÷ (total number 
of red-cell units transfused) among patients assigned to the standard-blood group.
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Primary Outcome
At 90 days after randomization, 448 of 1211 pa-
tients (37.0%) in the fresh-blood group and 430 
of 1219 patients (35.3%) in the standard-blood 
group had died. The unadjusted absolute risk dif-
ference was 1.7 percentage points (95% confi-
dence interval [CI], −2.1 to 5.5), and the adjusted 
risk difference was also 1.7 percentage points 
(95% CI, −1.6 to 4.9) (Fig. 1).
Secondary Analyses
The survival analysis of the time to death showed 
a hazard ratio in the fresh-blood group, as com-
pared with the standard-blood group, of 1.1 (95% 
CI, 0.9 to 1.2) (P = 0.38) (Fig. 2). No significant 
difference in mortality was observed between the 
groups on the basis of age, number of units 
transfused, APACHE II score, or admission cate-
gory (Fig. S3 in the Supplementary Appendix). 
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Figure 1. Forest Plot of Absolute Risk Differences in Primary and Secondary Outcomes.
All estimates have 95% confidence intervals that include zero but fall on the “standard blood better” side of the line. The Multiple Organ 
Dysfunction Score (MODS) ranges from 0 to 24, with higher scores indicating more severe organ dysfunction.17 The delta MODS is the 
difference between the MODS at randomization and the highest daily MODS observed thereafter. ICU denotes intensive care unit.
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No significant differences were observed with 
respect to major illnesses, duration of respirato-
ry, hemodynamic, or renal support, or length of 
stay in the ICU or hospital. Acute transfusion re-
actions occurred in four patients in the fresh-
blood group and six patients in the standard-blood 
group (Table S3 in the Supplementary Appendix).
We performed a per-protocol analysis of the 
primary outcome that included only patients 
who received a transfusion. At 90 days, 423 of 
1153 patients (36.7%) in the fresh-blood group 
and 398 of 1163 patients (34.2%) in the stan-
dard-blood group had died (absolute risk differ-
ence, 2.5 percentage points; 95% CI, −1.4 to 6.4). 
We also performed a sensitivity analysis of the 
primary outcome in which we compared the 
outcomes of the 967 patients in the fresh-blood 
group who received only red cells that had been 
stored for less than 8 days versus the outcomes 
in the 1084 patients in the standard-blood group 
who received red cells that had been stored for 
more than 7 days. In this sensitivity analysis, the 
number of deaths at 90 days was 357 (36.9%) in 
the fresh-blood group and 370 (34.1%) in the 
standard-blood group (absolute risk difference, 
2.8 percentage points; 95% CI, −1.4 to 6.9).
Discussion
The ABLE study did not show any benefit attrib-
utable to the transfusion of fresh red cells in 
critically ill patients. Not only were the primary 
outcomes similar in the two study groups, but 
the results were consistent in all per-protocol and 
subgroup analyses. These findings have impor-
tant implications for the critical care and blood-
transfusion communities. We surmise that the 
use of fresh red cells is not justified at this time. 
We might also infer that changes to red cells or 
the storage medium that have been documented 
in many laboratory studies18 may have limited 
clinical consequences.
The results of our trial are consistent with 
those of seven randomized, controlled trials that 
compared various durations of red-cell storage. 
Five pilot trials did not detect clinically impor-
tant clinical consequences of prolonged red-cell 
storage.10,11,19-21 Moreover, in two larger trials, 
transfusion of fresh red cells, as compared with 
standard-issue red cells, did not reduce the com-
plications of prematurity in very-low-birth-weight 
infants22 or reduce the rates of organ failure or 
adverse events among 1098 patients undergoing 
elective cardiac surgical procedures.23,24
Our findings are not consistent with those of 
some previous observational studies that sug-
gested that prolonged red-cell storage may be 
deleterious.5,9,25-27 More than 40 observational 
studies have examined the effect of red-cell stor-
age on various clinical outcomes, including mor-
tality, rates of infection, and length of stay in the 
hospital. Although the initial studies showed an 
association between longer red-cell storage and 
adverse outcomes, these associations may have 
been spurious owing to sicker patients receiving 
more units with longer storage, the overlap be-
tween comparison groups in the age of the red 
cells transfused, and the inclusion of transfu-
sions that occurred after the clinical events.28 
Results from more recent studies have been 
more balanced, with many studies showing no 
significant association between increased dura-
tion of red-cell storage and a worse outcome or 
showing worse outcomes with fresh red cells.29-31
Our trial has a number of strengths. It was suf-
ficiently large to detect clinically important differ-
ences in 90-day mortality. In addition, we enrolled 
a wide spectrum of critically ill patients, ensuring 
broad applicability of our findings. Bias was mini-
mized by concealed randomization, blinded study-
group assignments, and a rate of loss to follow-
up of less than 5%. The between-group difference 
in the duration of red-cell storage was statistically 
and clinically significant. The primary outcome 
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Figure 2. Kaplan–Meier Survival Analysis of Time to Death in the Intention-
to-Treat Population.
The intention-to-treat population included 2430 patients. The hazard ratio 
in the fresh-blood group, as compared with the standard-blood group, was 
1.1 (95% CI, 0.9 to 1.2).
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was clinically relevant and important to both 
patients and medical decision makers.
Limitations of this trial include the possibil-
ity that some groups of critically ill patients who 
are particularly vulnerable to the adverse conse-
quences of prolonged red-cell storage were under-
represented in the trial. Overall, most patients 
received transfusions according to a restrictive 
transfusion strategy, with a mean pretransfusion 
hemoglobin level of 7.7 g per deciliter, even in the 
absence of guidelines or protocols. Thus, expo-
sure to any red cells in this trial was much less 
than what would be the case at centers that are 
still opting for more liberal use of blood transfu-
sions. Although the testing of shorter storage 
times might have led to different results, we 
selected a 7-day storage threshold for the fresh-
blood group because blood-transfusion consul-
tants suggested that post-trial implementation 
of a shorter storage period would not be feasible, 
especially given the requirement for infectious-
disease testing (which takes up to 72 hours) and 
the finite number of blood donors.
We included only centers that used leukore-
duced red cells; therefore, whether leukocytes 
worsen the degradation of red cells during stor-
age or have other toxic effects that are enhanced 
by prolonged storage is uncertain. Only SAGM-
suspended red cells were used in the trial, be-
cause this is the standard red-cell product that 
is supplied in Canada and Europe. Red cells 
suspended in additive solution 3 (AS-3), which 
are supplied in the United States, are similar. 
However, there are differences in the method of 
production and in storage solutions. The storage 
solutions result in similar, though not identical, 
in vitro red-cell defects,32 suggesting that our 
results may be generalizable. Finally, we asked 
“Is fresh blood better than old blood?” rather 
than “Is old blood bad?”33 Our trial does not ad-
dress the issue of whether the use of red cells 
stored for very prolonged periods (35 to 42 days) 
results in harm.
In conclusion, we did not detect any clinically 
important improvements in primary or second-
ary outcomes among critically ill adults who re-
ceived transfusions of fresh red cells. 
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